drugset / Trial / NCT07229716

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

NCT07229716

Phase 1 Recruiting 20 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

Timeline

Start
2026-04-04
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-9813 Unknown Oral
Subject Nintedanib Small molecule
Subject Pirfenidone Small molecule

Indications